Sort
30,917 grants matching “tumor microenvironment”
Physical and Chemical Cues in Tumor Cell Migration
$414,194Cynthia A Reinhart-King · Cornell University · U54 · FY2011 · CA
Pathophysiologic Regulation of Fgf-23 in Phosphate Homeostasis: Role of Vitamin D
$414,127Beate Lanske · Harvard Medical School · R01 · FY2009 · DK
C MYC TARGETS IN THE PATHOGENESIS OF HUMAN CANCERS
$414,098Chi V. Dang · University Of Pennsylvania · R01 · FY2014 · CA
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers
$414,073Zachary Conrad Hartman · Duke University · R01 · FY2020 · CA
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
$414,033Manish Aghi · University Of California, San Francisco · R01 · FY2021 · CA
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$413,965Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
$413,953Song Li · University Of California Los Angeles · R01 · FY2021 · CA
Real time colon histopathology by infrared spectroscopic imaging
$413,952Rohit Bhargava · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA
Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy
$413,943Stanley R Riddell · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
POTENTIATING BREAST CANCER THERAPIES BY TARGETING TUMOR-ASSOCIATED MACROPHAGE
$413,872Suzie H Pun · University Of Washington · R01 · FY2017 · CA
Personalizing immunotherapy in HER2+ breast cancer through quantitative imaging
$413,866Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2022 · CA
Intra- and inter-cellular signals that drive hepato-oncogenesis
$413,831Gen-Sheng Feng · University Of California, San Diego · R01 · FY2023 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$413,778Robert M Prins · University Of California Los Angeles · P50 · FY2024 · CA
Nanotherapeutic treatment of the invasive glioblastoma microenvironment
$413,777Graeme F Woodworth · University Of Maryland Baltimore · R01 · FY2019 · NS
Surgical Studies on the Role on Gastrin-releasing Peptide in Neuroblastoma
$413,733Dai H Chung · Vanderbilt University · R01 · FY2015 · DK
Macrophages induce a tumor-promoting stable EMT in prostate cancer
$413,728Kenneth J. Pienta · University Of Michigan At Ann Arbor · P01 · FY2019 · CA
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
$413,727Venuprasad K Poojary · Ut Southwestern Medical Center · R01 · FY2022 · AI
Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
$413,715Daniel Abate-Daga · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Role of Osterix+ Osteolineage Cells in Primary and Metastatic Breast Cancer
$413,711Roberta Faccio · Washington University · R01 · FY2025 · CA
A platform for multi-modal single nucleus spatial genomics for molecular tumor analysis
$413,641Fei Chen · Broad Institute, Inc. · R33 · FY2025 · CA
Understanding the Behavior of Novel IL13Ralpha2-directed T cell Engager for GBM
$413,641Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2021 · NS
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts
$413,601Haval Shirwan · University Of Missouri-Columbia · U01 · FY2020 · AI
Chemical Exchange Saturation Transfer (CEST) MRI for the Characterization Small Renal Masses
$413,584Elena Vinogradov · Ut Southwestern Medical Center · R01 · FY2022 · CA
Targeted inhibition of eIF5Ahpu suppresses tumor growth and M2-like TAM polarization in oral cancer
$413,522Anh D Le · University Of Pennsylvania · R01 · FY2025 · DE
E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
$413,515Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · AI